Sinopharm Group Co. Ltd.
Sinopharm Group Co. Ltd. (SHTDY) Revenue
Annual & quarterly revenue history · segment & region breakdown
SHTDY · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsSinopharm Group Co. Ltd. trailing twelve-month (TTM) revenue is $1154B, a decrease of 4.28% year-over-year from $559B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $559B | -$25.01B | -4.28% |
| 2024-12-31 | $585B | -$12.06B | -2.02% |
| 2023-12-31 | $597B | +$44.42B | +8.05% |
| 2022-12-31 | $552B | +$31.10B | +5.97% |
| 2021-12-31 | $521B | +$64.64B | +14.16% |
| 2020-12-31 | $456B | +$31.14B | +7.32% |
| 2019-12-31 | $425B | +$80.75B | +23.44% |
| 2018-12-31 | $345B | +$67.50B | +24.36% |
| 2017-12-31 | $277B | +$18.91B | +7.33% |
| 2016-12-31 | $258B | +$29.44B | +12.88% |
Compare revenue vs peers
Medical - DistributionCompare SHTDY revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Sinopharm Group Co. Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Sinopharm Group Co. Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from Sinopharm Group Co. Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
SHTDY revenue · 4 questionsSHTDY's trailing twelve-month (TTM) revenue is $1154B. That is a decrease of 4.28% year-over-year from $559B in FY2025.
▸ Source: FMP · Sinopharm Group Co. Ltd. SEC filings · GAAP · Sinopharm Group Co. Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026